[{"orgOrder":0,"company":"Oncodesign","sponsor":"Servier","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"FRANCE","productType":"Small molecule","year":"2020","type":"Partnership","leadProduct":"Undisclosed","moa":"LRRK2 kinase","graph1":"Neurology","graph2":"Undisclosed","graph3":"Oncodesign","amount2":0.35999999999999999,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0.35999999999999999,"dosageForm":"","sponsorNew":"Oncodesign \/ Servier","highestDevelopmentStatusID":"1","companyTruncated":"Oncodesign \/ Servier"},{"orgOrder":0,"company":"Oncodesign","sponsor":"Tiumbio","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"","productType":"Small molecule","year":"2021","type":"Collaboration","leadProduct":"Nanocyclix Drug Candidates","moa":"kinase","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Preclinical","graph3":"Oncodesign","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"","sponsorNew":"Oncodesign \/ Oncodesign","highestDevelopmentStatusID":"4","companyTruncated":"Oncodesign \/ Oncodesign"},{"orgOrder":0,"company":"Oncodesign","sponsor":"SEngine Precision Medicine","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"kinase","graph1":"Oncology","graph2":"Discovery","graph3":"Oncodesign","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Oncodesign \/ Oncodesign","highestDevelopmentStatusID":"2","companyTruncated":"Oncodesign \/ Oncodesign"},{"orgOrder":0,"company":"Oncodesign","sponsor":"Servier","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Oncodesign","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Oncodesign \/ Servier","highestDevelopmentStatusID":"2","companyTruncated":"Oncodesign \/ Servier"}]

Find Clinical Drug Pipeline Developments & Deals by Oncodesign

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Under the terms of the agreement, Servier and OPM (through its OncoSNIPE program®) will be responsible for clinical research activities. Servier will fund the associated research costs. The target identification program will be funded by OPM and Servier...

                          Brand Name : Undisclosed

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          September 22, 2022

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Oncology

                          Highest Development Status : Discovery

                          Sponsor : Servier

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          02

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : SEngine and Oncodesign have initiated a joint research collaboration to evaluate the feasibility to convert the already identified Nanocyclix® inhibitor series into drug candidates that are likely to be effective in the clinic.

                          Brand Name : Undisclosed

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          February 08, 2022

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Oncology

                          Highest Development Status : Discovery

                          Recipient : SEngine Precision Medicine

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          03

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Under this agreement, Oncodesign will be responsible for identification, chemical synthesis and optimization of Nanocyclix drug candidates and their early-stage analysis, while TiumBio will be responsible for the advanced evaluation of fibrotic efficacy ...

                          Brand Name : Undisclosed

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          October 21, 2021

                          Lead Product(s) : Nanocyclix Drug Candidates

                          Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                          Highest Development Status : Preclinical

                          Recipient : Tiumbio

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          04

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : The partnership drew on the complementary expertise of Servier and Oncodesign in the fields of neurodegenerative diseases and macrocyclic kinase inhibitors.

                          Brand Name : Undisclosed

                          Molecule Type : Small molecule

                          Upfront Cash : $3.3 million

                          February 17, 2020

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Neurology

                          Highest Development Status : Undisclosed

                          Sponsor : Servier

                          Deal Size : $363.3 million

                          Deal Type : Partnership

                          blank